PL
NGM

Parkwood LLC’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Parkwood LLC’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-68,314
Closed -$73K – 169
2023
Q3 		$73K Hold
68,314
– – 0.01% 132
2023
Q2 		$177K Hold
68,314
– – 0.03% 121
2023
Q1 		$279K Hold
68,314
– – 0.04% 133
2022
Q4 		$343K Buy
68,314
+24,000
+54% +$150K 0.05% 126
2022
Q3 		$580K Buy
+44,314
New +$671K 0.09% 112
2021
Q4 		– Sell
-50,000
Closed -$1.05M – 139
2021
Q3 		$1.05M Buy
+50,000
New +$1.1M 0.13% 93

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parkwood LLC's NGM Position: Q4 2023 in Review

Parkwood LLC sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q4 2023, closing a stake of 68,314 shares — an estimated $73K sold.

Parkwood LLC first reported a position in NGM in Q3 2021 and held it in 6 quarters. The position peaked at $1.05M in Q3 2021. 83 funds tracked by Wall St. Rank hold NGM as of Q4 2023.

  • Parkwood LLC reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Parkwood LLC sold 68,314 NGM Biopharmaceuticals, Inc. Common Stock shares in Q4 2023, an estimated $73K.
  • Parkwood LLC first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q3 2021 and held it in 6 quarters.
  • Parkwood LLC's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $1.05M in Q3 2021.
  • 83 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q4 2023.

Based on Parkwood LLC's 13F filing for Q4 2023, filed 14 Feb 2024.